These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 38064104)

  • 1. Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer's Disease.
    Sequeira RC; Godad A
    Mol Neurobiol; 2024 Jul; 61(7):4203-4221. PubMed ID: 38064104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target.
    Mandlik DS; Mandlik SK; S A
    Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
    Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
    Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
    Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
    Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GSK-3 and Tau: A Key Duet in Alzheimer's Disease.
    Sayas CL; Ávila J
    Cells; 2021 Mar; 10(4):. PubMed ID: 33804962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment.
    Pal D; Mukherjee S; Song IH; Nimse SB
    Curr Drug Targets; 2021; 22(15):1725-1737. PubMed ID: 33459229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer's Disease-Related Epileptic Seizures.
    Lin R; Jones NC; Kwan P
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
    Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
    Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
    Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
    CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase-3 signaling in Alzheimer's disease.
    Lauretti E; Dincer O; Praticò D
    Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118664. PubMed ID: 32006534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects.
    Cheng Z; Han T; Yao J; Wang K; Dong X; Yu F; Huang H; Han M; Liao Q; He S; Lyu W; Li Q
    Eur J Med Chem; 2024 Feb; 265():116065. PubMed ID: 38160617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GSK-3 is essential in the pathogenesis of Alzheimer's disease.
    Takashima A
    J Alzheimers Dis; 2006; 9(3 Suppl):309-17. PubMed ID: 16914869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-219-5p inhibits tau phosphorylation by targeting TTBK1 and GSK-3β in Alzheimer's disease.
    Li J; Chen W; Yi Y; Tong Q
    J Cell Biochem; 2019 Jun; 120(6):9936-9946. PubMed ID: 30556160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach.
    Sharma V; Chander Sharma P; Reang J; Yadav V; Kumar Tonk R; Majeed J; Sharma K
    Bioorg Chem; 2024 Jun; 147():107378. PubMed ID: 38643562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
    Lovestone S; Reynolds CH; Latimer D; Davis DR; Anderton BH; Gallo JM; Hanger D; Mulot S; Marquardt B; Stabel S
    Curr Biol; 1994 Dec; 4(12):1077-86. PubMed ID: 7704571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
    Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
    Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease.
    Huang HC; Klein PS
    Curr Drug Targets; 2006 Nov; 7(11):1389-97. PubMed ID: 17100579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.